Nitric oxide synthase and polycystic kidney disease

Viroj Wiwanitkit*
Surin Rajabhat University, Surin, Thailand

**A R T I C L E  I N F O**

**Article Type:**
Hypothesis

**Article History:**
Received: 3 May 2015
Accepted: 2 June 2015
ePublished: 20 June 2015

**Keywords:**
Nitric oxide synthase
Polycystic kidney disease
Chronic kidney disease

**Implication for health policy/practice/research/medical education:**
Endothelial nitric oxide plays a crucial role in the control of local hemodynamics and systemic blood pressure. Thus, it has been proposed that gene coding for endothelial nitric oxide synthase (eNOS) could have a modifying effect on hypertension and related complications in autosomal dominant polycystic kidney disease (ADPKD). As endothelial dysfunction and oxidative stress are evident early in ADPKD patients, eNOS holds therapeutic promise in the treatment of ADPKD.

**Please cite this paper as:** Wiwanitkit V. Nitric oxide synthase and polycystic kidney disease. J NephroPharmacol. 2015;4(2):85-87.

Polycystic kidney disease (PKD) is a multisystem disorder characterized by the formation of cysts within the kidneys. PKD is mainly caused by the unfolding of its immunoglobulin-like PKD domains. There are two major forms of PKD; autosomal dominant (ADPKD) that caused by mutations of PKD1 and PKD2 (1) and autosomal recessive (ARPKD) caused by mutations in PKHD1 gene (2,3). Although, cellular changes and mechanisms involved in initial stages of cyst formation might differ between ADPKD and ARPKD, both are important causes of kidney failure, morbidity and mortality in children and adults of all racial groups worldwide (4). Further, it is clear that the disease progression in the ADPKD and ARPKD involves almost similar pathogenetic mechanisms (5,6). Hypertension is an important factor in the progression of kidney failure ADPKD patients, 60% of ADPKD patients exhibit high blood pressure even before the impairment of kidney function (7).

Accumulating evidence, including findings of elevation of arterial blood pressure in mice lacking the endothelial nitric oxide synthase (eNOS) gene, strongly suggests that alteration in NO metabolism is implicated in hypertension (8). Nitric oxide synthases (NOSs) catalyze the conversion of L-arginine into L-citrulline and nitric oxide (9,10). The gene coding for endothelial NOS (NOS3) is located on chromosome 7q35-36 (11) and harboring several polymorphic variants that can alter nitric oxide synthesis. These include, promoter polymorphism (-786T > C), Glu298Asp is a missense variant in exon 7 and 27-base pair (bp) variable number of tandem repeat in intron-4. The -786 C allele of promoter polymorphism acts as a repressor of NOS3 transcription (12). The Glu298Asp and intron-4 VNTR are also known to alter endothelial NOS expression (11,13). Various studies have shown that nitric oxide synthase gene polymorphisms in PKD. A recent report on “nitric oxide synthase VNTR (intron 4 a/b) polymorphism and PKD” is very interesting (14). Elumalai et al studied the clinical relationship between VNTR genetic polymorphism and clinical course in patients with ADPKD (14). Elumalai et al showed the “significant association between the 27-bp VNTR and chronic kidney disease (CKD) advancement among the ADPKD patients in the South Indian population (14). The other study by analyzing four tagging SNPs and two more well studied polymorphisms (Intron 4 VNTR and Glu298Asp) of the NOS3 gene investigated to identify the potential modifier effect of NOS3 gene on the progression of CKD in ADPKD (15). However, they did not find any evidence for the involvement of NOS3 tag-SNPs in the progression to CKD in ADPKD patients (15). Direct analysis of NOS3 gene polymorphisms in ADPKD patients has also revealed inconclusive results from many populations (Table 1).

Multiple studies have shown that nitric oxide negatively regulates the renin-angiotensin aldosterone system (RAAS) by inhibiting ACE activity and angiotensin II type 1 receptors (27). Use of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) in controlling the CKD progression is further supporting the role of endothelial nitric oxide synthase.

*Corresponding author: Professor Viroj Wiwanitkit, Email: wviroj@yahoo.com
Evidence suggests that endothelial nitric oxide synthase (NOS3) is post-translationally lysine acetylated, leading to increased NO production in the endothelium. Expression of NOS3 is not only controlled by gene polymorphisms but also by its HDAC-dependent posttranscriptional regulation (28). Endothelial dysfunction and oxidative stress are evident early in ADPKD patients, even in those with preserved kidney function. Hence, HDAC1-mediated deacetylation of NOS3 may represent a novel target for regulation of NOS3 expression and enzyme activity. FEBS Lett. 1993;353:103-7.

Author's contribution
VW is the single author of the manuscript.

Conflicts of interest
The author declared no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.

Funding/Support
None.

References
1. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353:103-7.
2. Bergmann C, Kupper F, Schmitt CP, Vester U, Neuhaus TJ, Sander J, et al. Multi-exon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease (ARPKD). J Med Genet. 2005;42:e63.
3. Sharp AM, Messiaen LM, Page G, Antignac C, Gubler MC, Onuchic LF, et al. Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet. 2005;42:336-49.
4. Gabow PA. Autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:511-2.
5. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Biol. 2010;191:701-10.
6. Terryn S, Ho A, Beaumens R, Devuyst O. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta. 2011;1812:1314-21.
7. Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1992;20:140-3.
8. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, et al. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol. 2007;18:730-40.
9. Vanhoutte PM, Mombouli JV. Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis. 1996;39:229-38.
10. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med. 1999;92(4):164-9.
11. Marsden PA, Heng HH, Scherer SW, Stewart RI, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268:17478-88.
12. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K, et al. T(-786)--> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000;86:628-34.
13. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett. 2000;471:45-50.
14. Elumalai R, Periasamy S, Ramanathan G, Lakkakula BV. Role of endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease. J Renal Inj Prev. 2014;3:69-73.
15. Ramanathan G, Periyasamy S, Lakkakula BV. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease. Nephrology (Carlton). 2014;19:537-41.

16. Persu A, Stoienoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet. 2002;11:229-41.

17. Tazon-Vega B, Vilardell M, Perez-Oller L, Ars E, Ruiz P, Devuyst O, et al. Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1. Nephrol Dial Transplant. 2007;22:1567-77.

18. Dasar N, Ghaderian S, Azargashb E. Human Evaluation of the Glu298Asp polymorphism in NOS3 gene and its relationship with onset age of ESRD in Iranian patients suffering from ADPKD. Int J Mol Cell Med. 2012;1:105-12.

19. Suzuki H, Nagase S, Kikuchi S, Wang Y, Koyama A. Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. Clin Chem. 2000;46:1858-60.

20. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension. 2002;40:535-40.

21. Walker D, Consugar M, Slezak J, Torres VE, Winearls CG, et al. The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease. J Am J Kidney Dis. 2003;41:90-4.

22. Reiterova J, Miroslav M, Stekrova J, Kmentova D, et al. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Ren Fail. 2002;24:585-93.

23. Lamnissou K, Zirogiannis P, Trygonis S, Demetriou K, Pierides A, Koptides M, et al. Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus. Genet Test. 2004;8:319-24.

24. Fernandez-Alfonso MS, Gonzalez C. Nitric oxide and the renin-angiotensin system. Is there a physiological interplay between the systems? J Hypertens. 1999;17:1355-61.

25. Hyndman KA, Ho DH, Sega MF, Pollock JS. Histone deacetylase 1 reduces NO production in endothelial cells via lysine deacetylation of NO synthase 3. Am J Physiol Heart Circ Physiol. 2014;307:H803-9.

26. Cao Y, Semanchik N, Lee SH, Somlo S, Barbano PE, Coifman R, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci U S A. 2009;106:21819-24.